Table 1 Approved immune checkpoint blockade therapies

PD-1

Nivolumab

Bristol-Meyers Squibb Company Inc.

Metastatic small cell lung cancer

Progression after platinum-based chemotherapy and at least one other line of therapy

August 16, 2018

[151]

Metastatic colorectal cancer

Ipilimumab

Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

July 10, 2018

[152]

Untreated advanced renal cell carcinoma

Ipilimumab

April 16, 2018

[153]

Melanoma

Adjuvant treatment

Involvement of lymph nodes

December 20, 2017

[154]

Hepatocellular carcinoma

September 22, 2017

[155]

Metastatic colorectal cancer

Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H)

July 31, 2017

[156]

Locally advanced or metastatic urothelial carcinoma

February 2, 2017

[157]

Squamous cell carcinoma of the head and neck

November 10, 2016

[158]

Classic Hodgkin lymphoma

May 17, 2016

[159]

Advanced renal cell carcinoma

November 23, 2015

[160]

Metastatic non-small cell lung cancer

October 9, 2015

[161]

Metastatic melanoma

Ipilimumab

BRAF V600 wild type

September 30, 2015

[162]

Metastatic squamous non-small cell lung cancer

March 4, 2015

[163]

Unresectable or metastatic melanoma

December 22, 2014

[164]

Pembrolizumab

Merck & Co, Inc.

Non-small cell lung cancer

Carboplatin and either paclitaxel or nab-paclitaxel

October 30, 2018

[165]

Metastatic, non-squamous non-small cell lung cancer

Pemetrexed and platinum

August 20, 2018

[166]

Primary mediastinal large B cell lymphoma

June 13, 2018

[167]

Metastatic cervical cancer

Express PD-L1 (combined positive score ≥ 1)

June 12, 2018

[168]

Gastric or gastroesophageal junction adenocarcinoma

Express PD-L1

September 22, 2017

[169]

Solid tumors

Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

May 23, 2017

[170]

Urothelial carcinoma

May 18, 2017

[171]

Metastatic non-squamous non-small cell lung cancer

Pemetrexed and carboplatin

May 10, 2017

[172]

Classic Hodgkin lymphoma

March 14, 2017

[173]

Metastatic non-small cell lung cancer

Express PD-L1

October 24, 2016

[174]

Recurrent or metastatic head and neck squamous cell carcinoma

August 5, 2016

[175]

Unresectable or metastatic melanoma

December 18, 2015

[176]

Metastatic non-small cell lung cancer

Express PD-L1

October 2, 2015

[177]

Unresectable or metastatic melanoma

Following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor

September 4, 2014

[178]

PD-L1

Atezolizumab

Genentech Oncology

Metastatic non-small cell lung cancer

October 18, 2016

[179]

Locally advanced or metastatic urothelial carcinoma

May 18, 2016

[180]

Durvalumab

AstraZeneca Inc.

Stage III non-small cell lung cancer

February 16, 2018

[181]

Locally advanced or metastatic urothelial carcinoma

May 1, 2017

[182]

Avelumab

EMD Serono, Inc.

Metastatic Merkel cell carcinoma

March 23, 2017

[183]

CTLA-4

Ipilimumab

Bristol-Meyers Squibb Company, Inc.

Metastatic colorectal cancer

Nivolumab

Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

July 10, 2018

[152]

Untreated advanced renal cell carcinoma

Nivolumab

April 16, 2018

[153]

Cutaneous melanoma

October 28, 2015

[184]

BRAF V600 wild-type, unresectable or metastatic melanoma

Nivolumab

September 30, 2015

[162]